Mobile

A Phase III, randomised, double blind, placebo controlled study to evaluate the safety and efficacy of subcutaneous implants of CUV1647 in patients suffering from polymorphic light eruption (PLE)

Mise à jour : Il y a 4 ans
Référence : EUCTR2006-005321-40

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

•Evaluate whether CUV1647 prevents episodes or reduces the severity of symptoms in patients with PLE •Evaluate the safety and tolerability of CUV1647 •Evaluate the effect of CUV1647 on the use of rescue medication for the treatment of PLE symptoms •Evaluate the effect of CUV1647 on melanin density measured by skin reflectance

Critère d'inclusion

  • Polymorphic light eruption (PLE)

Liens